HUTCHMED (HCM) Competitors $15.87 -0.13 (-0.81%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$15.88 +0.01 (+0.06%) As of 08/14/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HCM vs. MRNA, VRNA, BBIO, BPMC, ELAN, ROIV, GRFS, LEGN, RVMD, and RYTMShould you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry. HUTCHMED vs. Its Competitors Moderna Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Elanco Animal Health Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals HUTCHMED (NASDAQ:HCM) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership. Does the media favor HCM or MRNA? In the previous week, Moderna had 8 more articles in the media than HUTCHMED. MarketBeat recorded 16 mentions for Moderna and 8 mentions for HUTCHMED. Moderna's average media sentiment score of 0.37 beat HUTCHMED's score of 0.36 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Which has more risk and volatility, HCM or MRNA? HUTCHMED has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.83, meaning that its stock price is 83% more volatile than the S&P 500. Is HCM or MRNA more profitable? HUTCHMED has a net margin of 0.00% compared to Moderna's net margin of -94.31%. HUTCHMED's return on equity of 0.00% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets HUTCHMEDN/A N/A N/A Moderna -94.31%-25.96%-20.09% Do analysts rate HCM or MRNA? HUTCHMED presently has a consensus target price of $28.00, suggesting a potential upside of 76.43%. Moderna has a consensus target price of $43.59, suggesting a potential upside of 63.31%. Given HUTCHMED's stronger consensus rating and higher possible upside, analysts clearly believe HUTCHMED is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HUTCHMED 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Moderna 4 Sell rating(s) 16 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.04 Which has higher valuation and earnings, HCM or MRNA? HUTCHMED has higher earnings, but lower revenue than Moderna. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHUTCHMED$630.20M4.39$37.73MN/AN/AModerna$3.24B3.21-$3.56B-$7.53-3.54 Do insiders and institutionals have more ownership in HCM or MRNA? 8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 11.0% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryModerna beats HUTCHMED on 8 of the 15 factors compared between the two stocks. Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HCM vs. The Competition Export to ExcelMetricHUTCHMEDMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.79B$3.10B$5.62B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.4930.2925.74Price / Sales4.39356.37463.41115.83Price / Cash55.7043.0338.2159.48Price / Book2.238.608.826.15Net Income$37.73M-$54.65M$3.25B$265.06M7 Day Performance5.80%5.86%3.71%2.60%1 Month Performance-4.17%8.86%5.85%2.83%1 Year Performance-19.24%13.33%29.92%25.58% HUTCHMED Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HCMHUTCHMED2.6309 of 5 stars$15.87-0.8%$28.00+76.4%-17.0%$2.79B$630.20M0.001,811Positive NewsMRNAModerna4.4658 of 5 stars$25.47-2.5%$43.59+71.1%-67.6%$10.16B$3.24B-3.385,800VRNAVerona Pharma PLC American Depositary Share2.3649 of 5 stars$105.240.0%$109.00+3.6%+285.5%$8.96B$42.28M-106.3030Positive NewsShort Interest ↓BBIOBridgeBio Pharma4.3617 of 5 stars$48.24+3.6%$61.35+27.2%+111.1%$8.90B$221.90M-11.79400Insider TradeBPMCBlueprint Medicines0.8451 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ELANElanco Animal Health2.904 of 5 stars$17.10+2.6%$17.33+1.3%+27.8%$8.28B$4.44B19.899,000Earnings ReportAnalyst ForecastAnalyst RevisionROIVRoivant Sciences2.7306 of 5 stars$11.17-2.8%$16.50+47.7%+2.8%$7.81B$29.05M-44.68860Gap DownGRFSGrifols3.7479 of 5 stars$10.60-0.6%$10.30-2.8%+55.4%$7.33B$7.81B9.0623,822Short Interest ↑LEGNLegend Biotech3.7431 of 5 stars$36.24-2.1%$73.33+102.4%-31.0%$6.80B$627.24M-61.422,609News CoverageEarnings ReportAnalyst ForecastRVMDRevolution Medicines3.7273 of 5 stars$34.70-0.9%$68.82+98.3%-15.4%$6.54B$11.58M-7.71250Analyst RevisionRYTMRhythm Pharmaceuticals3.7675 of 5 stars$94.31+2.5%$101.57+7.7%+110.3%$6.11B$130.13M-31.33140Trending NewsInsider TradeAnalyst Revision Related Companies and Tools Related Companies MRNA Alternatives VRNA Alternatives BBIO Alternatives BPMC Alternatives ELAN Alternatives ROIV Alternatives GRFS Alternatives LEGN Alternatives RVMD Alternatives RYTM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HCM) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access